The magnitude of TSPO binding, reflecting CNS inflammatory activity, is elevated in MS patients and serves as a reliable predictor of disease progression.1 3 Here, we show that the serum metabolome, specifically, the levels of glutamate, glutamine, and glucose, are predictive of progression within 1 year later. This evidence concerns the gene TSPO and myeloid sarcoma.